Strategy Asset Managers LLC decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,629 shares of the medical research company’s stock after selling 387 shares during the period. Strategy Asset Managers LLC’s holdings in Thermo Fisher Scientific were worth $3,050,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Hanson McClain Inc. lifted its stake in shares of Thermo Fisher Scientific by 263.9% in the fourth quarter. Hanson McClain Inc. now owns 131 shares of the medical research company’s stock valued at $29,000 after buying an additional 95 shares in the last quarter. Capital Investment Advisory Services LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $35,000. Gradient Investments LLC lifted its stake in shares of Thermo Fisher Scientific by 1,887.5% in the fourth quarter. Gradient Investments LLC now owns 159 shares of the medical research company’s stock valued at $36,000 after buying an additional 151 shares in the last quarter. WESPAC Advisors SoCal LLC lifted its stake in shares of Thermo Fisher Scientific by 70.0% in the fourth quarter. WESPAC Advisors SoCal LLC now owns 170 shares of the medical research company’s stock valued at $38,000 after buying an additional 70 shares in the last quarter. Finally, Doyle Wealth Management bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $38,000. 88.66% of the stock is owned by institutional investors and hedge funds.
TMO has been the topic of a number of recent research reports. BTIG Research raised their price objective on shares of Thermo Fisher Scientific to $290.00 and gave the company a “buy” rating in a research note on Thursday, January 31st. Barclays raised their price target on shares of Thermo Fisher Scientific from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, January 3rd. Needham & Company LLC started coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, January 2nd. They set a “strong-buy” rating and a $271.00 price target on the stock. UBS Group raised their price target on shares of Thermo Fisher Scientific to $305.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Finally, Deutsche Bank raised their price target on shares of Thermo Fisher Scientific from $275.00 to $300.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $289.00.
TMO stock traded down $3.09 during mid-day trading on Monday, hitting $277.56. The company had a trading volume of 1,707,704 shares, compared to its average volume of 1,606,346. The firm has a market cap of $111.98 billion, a price-to-earnings ratio of 24.96, a P/E/G ratio of 1.85 and a beta of 1.13. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.24 and a current ratio of 1.73. Thermo Fisher Scientific Inc. has a 12 month low of $202.83 and a 12 month high of $282.98.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 30th. The medical research company reported $3.25 EPS for the quarter, topping the consensus estimate of $3.19 by $0.06. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.26 billion. Thermo Fisher Scientific had a net margin of 12.06% and a return on equity of 16.86%. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.79 earnings per share. Analysts forecast that Thermo Fisher Scientific Inc. will post 12.15 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 16th. Shareholders of record on Friday, March 15th will be given a $0.19 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. The ex-dividend date is Thursday, March 14th. This represents a $0.76 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is currently 6.83%.
COPYRIGHT VIOLATION WARNING: “Thermo Fisher Scientific Inc. (TMO) Shares Sold by Strategy Asset Managers LLC” was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/15/strategy-asset-managers-llc-decreases-stake-in-thermo-fisher-scientific-inc-tmo.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
See Also: Why Net Income is Important to Investors
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.